Kyowa Kirin researches, develops, manufactures and sells specialty medicines. Its technology platforms include antibodies and hematopoietic stem-cell gene therapy, with research focused on bone and mineral disorders, intractable blood diseases and blood cancers, and rare diseases.
Its products include Crysvita, an antibody against FGF23 used for X-linked hypophosphatemia, Poteligeo, an antibody targeting CCR4 on malignant T cells, and Nourianz for Parkinson's disease. Group companies sell medicines in Japan, Asia Pacific, North America and Europe, and approved indications differ between countries. The group had 5,161 consolidated employees as of December 31, 2025.
0
open positions at Kyowa Kirin
No live listings from Kyowa Kirin right now — browse all Tokyo software jobs instead.